Deal Coming To A Close On 'Green Whistle' Inhaler For Pain Relief
the Clinical Pain Advisor take:
Officials with Medical Developments International Limited announced they have agreed to a term sheet and will now move to contract with a pharmaceutical company having expertise in pain management products.
The agreement would enable Medical Developments to distribute Penthrox within the 28 member states of the European Union, except for the United Kingdom, Ireland, and Hungary where MDI has existing distribution agreements, and within other European countries.
The potential transaction calls for upfront and milestone payments of $54.5 million including:
- $7.0 million upon signing.
- $3.0 million upon receiving Marketing Authorisation approvals in France (expected very shortly) and Belgium (already received).
- $7.0 million upon receiving reimbursement in Germany, Italy, Spain and France.
- The remaining $37.5 million relates to sales milestones potentially earned more than the term of the deal.
Additionally, MVP will receive a gross margin on product sold to partner and royalties based on net sales.
According to materials on Medical Development International's website, this medication is indicated for the relief of pain by "self administration in conscious hemodynamically stable patients with trauma and associated pain."
It is also indicated "for the relief of pain in monitored conscious patients who require analgesia for surgical procedures such as the change of dressings."
Clinical Pain Advisor Articles
- Non-Opioid Therapies for Pain Management in the ED
- CBT vs Pain Education for Chronic Pain in Low-Income Clinics
- Risks Associated With Intra-Articular Lumbar Facet Joint Injections of Triamcinolone Acetonide for Low Back Pain
- Factors Predicting Pain Outcomes After TKR for Knee Osteoarthritis
- Lumbar Disc Herniation With Radiculopathy Treatment Using Targeted Indwelling ESI
- Exploring the Connections Between Neuropathic Pain and Comorbid Mood Disorders
- Medical Marijuana Laws, Dispensaries May Reduce Deaths From Opioid Overdose
- Ketamine Infusion May Be Effective for the Short-Term Relief of CRPS-Associated Pain
- An Avenue for the Development of Opioid Adjuncts for Enhanced Analgesia, Reduced Abuse Potential
- Spinal Manipulative Therapy May Effectively Reduce Cervicogenic Headache Days
- Peripherally Acting Opioid and Cannabinoid May Be Effective for Neuropathic Pain
- Positive Affect, Resilience, and Pain in MS With Chronic Pain
- Addressing Clinician Burnout at the Institutional Level
- Glucosamine vs Ibuprofen for Painful Temporomandibular Joint Osteoarthritis
- Chronic Pain in Adolescents and Alexithymia